Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | SCN4A | P35499 | 10/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668708 | 0.78 | SCN4A (0.53) | TACR1SCN4A | |
| SCHEMBL4990397 | 0.77 | SCN4A (0.63) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL19668463 | 0.77 | SLC6A4 (0.46) | CACNA1CNOS3NOS2IDO1TDO2 | |
| SCHEMBL19668648 | 0.77 | TACR1 (0.67) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL22474623 | 0.76 | NOS3 (0.44) | NOS3NOS2 | |
| SCHEMBL19668457 | 0.76 | SCN4A (0.59) | TACR1SCN4AAKT1 | |
| SCHEMBL19686722 | 0.75 | SCN4A (0.55) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL19686204 | 0.74 | SCN4A (0.54) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL19154982 | 0.71 | NPC1 (0.56) | NOS3NOS2 | |
| SCHEMBL19732851 | 0.71 | NOS3 (0.50) | NOS3NOS2IDO1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492325-B2 | Compounds as inhibitors of sodium channels | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2022-11-08 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3494105-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | Human Biomolecular Research Institute (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | TACR1 174/4885CACNA1F 18/4885CACNA1D 10/4885 |
| US-11492325-B2 | Compounds as inhibitors of sodium channels | SCN1B, CACNA1E, SCN2B | TACR1 174/4885CACNA1F 18/4885CACNA1D 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.